The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy and Safety of Peginterferon Alfa-2A (40Kd) Plus Ribavirin in Hepatitis C Patients With Advanced Fibrosis and Cirrhosis
Open accessAbstract
The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. Conclusion: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR. (Hepatology 2010.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Cited by
Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., Guyader, D., Fontaine, H., Larrey, D., De Lédinghen, V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.009 · Cited by 538
Self-citationEvidence-based clinical practice guidelines for liver cirrhosis 2015
Fukui, H., Saito, H., Ueno, Y., Uto, H., Obara, K., Sakaida, I., Shibuya, A., Seike, M., Nagoshi, S., Segawa, M., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1216-y · Cited by 306
Influence of the inflammatory response on treatment of hepatitis C with triple therapy
Winckler, F. C., Braz, A. M. M., Silva, V. N. D., Golim, M. D. A., Andrade, V. G. D., Machado, P. E. D. A., Silveira, L. V. D. A., & Silva, G. F. (2018) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0137-2018 · Cited by 2
Metadata
- Authors
- Bruno, S., Shiffman, M. L., Roberts, S. K., Gane, E. J., Messinger, D., Hadziyannis, S. J., & Marcellin, P.
- Venue
- Hepatology
- Published
- 2010-02
- Volume
- 51
- Issue
- 2
- Pages
- 388-397
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2015973940
- Cited by
- 160
- References
- 1
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Peginterferon Alfa-2A (40Kd) Plus Ribavirin in Hepatitis C Patients With Advanced Fibrosis and Cirrhosis. https://app.cochat.ai/papers/10.1002/hep.23340
- The paper
- Bruno, S., Shiffman, M. L., Roberts, S. K., Gane, E. J., Messinger, D., Hadziyannis, S. J., & Marcellin, P. (2010). Efficacy and Safety of Peginterferon Alfa-2A (40Kd) Plus Ribavirin in Hepatitis C Patients With Advanced Fibrosis and Cirrhosis. Hepatology. https://doi.org/10.1002/hep.23340
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.